Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.71 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | NLN | Q9BYT8 | 3/20 | 0.53 |
| ▸ | TRHR | P34981 | 1/20 | 0.52 |
| ▸ | ARG1 | P05089 | 2/20 | 0.47 |
| ▸ | ARG2 | P78540 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 3/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477930 | 1.00 | DPP4 (0.71) | DPP4DPP7CYP3A4SLC7A5NLN | |
| SCHEMBL27210419 | 1.00 | DPP4 (0.71) | DPP4DPP7CYP3A4SLC7A5NLN | |
| SCHEMBL30839655 | 0.87 | DPP4 (0.66) | DPP4DPP7CYP3A4SLC7A5NLN | |
| SCHEMBL27273680 | 0.86 | DPP4 (0.56) | DPP4DPP7CYP3A4SLC7A5NLN | |
| SCHEMBL31649037 | 0.84 | DPP4 (0.71) | DPP4DPP7CYP3A4SLC7A5NLN | |
| SCHEMBL27484466 | 0.83 | DPP4 (0.69) | DPP4DPP7CYP3A4SLC7A5NLN | |
| SCHEMBL22300350 | 0.80 | DPP4 (0.56) | DPP4DPP7NLNTRHRREN | |
| SCHEMBL27726234 | 0.77 | NLN (0.64) | DPP4DPP7CYP3A4SLC7A5NLN | |
| SCHEMBL27210409 | 0.77 | TRHR (0.54) | DPP4TRHRRENACE | |
| SCHEMBL5734357 | 0.77 | DPP4 (0.44) | DPP4DPP7RENHRH1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619020-A1 | COMPOSITION AND METHOD FOR PROLONG SURVIVAL OF TRANSPLANT AND RECIPIENT | NovMetaPharma Co., Ltd. (KR) | 2025-09-24 | — | — | EP | claimed |
| US-20240197816-A1 | COMPOSITION AND METHOD FOR PROLONG SURVIVAL OF TRANSPLANT AND RECIPIENT | NOVMETAPHARMA CO., LTD. (KR) | 2024-06-20 | — | — | US | claimed |
| CN-117677302-A | Peptide compounds for flavor modulation | CJ第一制糖株式会社 | 2024-03-08 | — | — | CN | claimed |
| CN-114380695-B | Novel method for simply and rapidly realizing C-C bond formation reaction | 吉林大学 | 2024-02-13 | — | — | CN | claimed |
| CN-85105655-A | Process for preparing novel derivatives of 1-methyl-4, 5-dihydroorotic acid and pharmaceutical compositions thereof | — | 1987-01-28 | — | — | CN | claimed |
| WO-2025230339-A1 | USE OF CYCLO-HISPRO ALONE OR ZINC AND CYCLO-HISPRO FOR INHIBITING MUSCLE LOSS OR ALLEVIATING MUSCLE FUNCTION DECLINE CAUSED BY ANTI-OBESITY DRUGS | 주식회사 노브메타파마 | 2025-11-06 | — | — | WO | disclosed |
| WO-2025230339-A1 | USE OF CYCLO-HISPRO ALONE OR ZINC AND CYCLO-HISPRO FOR INHIBITING MUSCLE LOSS OR ALLEVIATING MUSCLE FUNCTION DECLINE CAUSED BY ANTI-OBESITY DRUGS | 주식회사 노브메타파마 | 2025-11-06 | — | — | WO | disclosed |
| EP-4619020-A1 | COMPOSITION AND METHOD FOR PROLONG SURVIVAL OF TRANSPLANT AND RECIPIENT | NovMetaPharma Co., Ltd. (KR) | 2025-09-24 | — | — | EP | disclosed |
| CN-120112534-A | PEG modified cyclic dipeptides | 诺麦塔制药有限公司 | 2025-06-06 | — | — | CN | disclosed |
| CN-119925563-A | Small molecule peptide composition for repairing cerebral apoplexy brain cells based on stem cell targeting | 北京钦川科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119798264-A | Application of cyclo (-HIS-PRO) hydrate | 诺麦塔制药有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119798264-A | Application of cyclo (-HIS-PRO) hydrate | 诺麦塔制药有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-115666543-A | Coronavirus therapeutic agents and methods of treatment | 血管免疫治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-4122484-A1 | USE OF CYCLO-HISPRO (CHP) FOR LOWERING BLOOD PRESSURE | Novmetapharma Co., Ltd. (KR) | 2023-01-25 | — | — | EP | disclosed |
| US-11524979-B2 | Macrocyclic polypeptides | UNIVERSITY OF WASHINGTON (US) | 2022-12-13 | — | — | US | disclosed |
| EP-3967321-A1 | USE OF CYCLO-HIS-PRO (CHP) FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS | Novmetapharma Co., Ltd. (KR) | 2022-03-16 | — | — | EP | disclosed |
| EP-3383423-B1 | POLYPEPTIDES AND ANALOGUES THEREOF FOR USE IN THE TREATMENT OF DIABETES AND BONE DISORDERS | UNIV ULSTER (GB) | 2022-03-09 | — | — | EP | disclosed |
| EP-3949976-A1 | USE OF CYCLO HIS-PRO (CHP) FOR PREVENTING, ALLEVIATING OR TREATING PERITONEAL FIBROSIS | Novmetapharma Co., Ltd. (KR) | 2022-02-09 | — | — | EP | disclosed |
| CN-101951935-A | Therapeutic agent for cerebral ischemic disorder | OTSUKA PHARMA CO LTD | 2011-01-19 | — | — | CN | disclosed |
| CN-101309682-A | Modulation of neurogenesis by pde inhibition | BRAINCELLS INC (US) | 2008-11-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197816-A1 | COMPOSITION AND METHOD FOR PROLONG SURVIVAL OF TRANSPLANT AND RECIPIENT | CHP1, CETP, PCTP | DPP4 2308/4885DPP7 2208/4885CYP3A4 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.